Nasdaq:US$13.64 (-0.17) | HKEX:HK$20.55 (-0.50) | AIM:£2.19 (-0.08)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer